Literature DB >> 26310919

Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics.

C A Maschinot, J R Pace, M K Hadden1.   

Abstract

The hedgehog (Hh) pathway is a developmental signaling pathway that is essential to the proper embryonic development of many vertebrate systems. Dysregulation of Hh signaling has been implicated as a causative factor in the development and progression of several forms of human cancer. As such, the development of small molecule inhibitors of Hh signaling as potential anti-cancer chemotherapeutics has been a major area of research interest in both academics and industry over the past ten years. Through these efforts, synthetic small molecules that target multiple components of the Hh pathway have been identified and advanced to preclinical or clinical development. The goal of this review is to provide an update on the current status of several synthetic small molecule Hh pathway inhibitors and explore the potential of several recently disclosed inhibitory scaffolds.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26310919      PMCID: PMC5062741          DOI: 10.2174/0929867322666150827093904

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  119 in total

1.  The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors.

Authors:  Minhang Xin; Jun Wen; Feng Tang; Chongxing Tu; Han Shen; Xinge Zhao
Journal:  Bioorg Med Chem Lett       Date:  2013-10-17       Impact factor: 2.823

Review 2.  Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.

Authors:  Upasana Banerjee; Matthew Kyle Hadden
Journal:  Expert Opin Drug Discov       Date:  2014-05-22       Impact factor: 6.098

3.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Authors:  James Kim; Blake T Aftab; Jean Y Tang; Daniel Kim; Alex H Lee; Melika Rezaee; Jynho Kim; Baozhi Chen; Emily M King; Alexandra Borodovsky; Gregory J Riggins; Ervin H Epstein; Philip A Beachy; Charles M Rudin
Journal:  Cancer Cell       Date:  2013-01-03       Impact factor: 31.743

4.  Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.

Authors:  Jesus M Ontoria; Laura Llauger Bufi; Caterina Torrisi; Alberto Bresciani; Claudia Giomini; Michael Rowley; Sergio Serafini; Hu Bin; Wu Hao; Christian Steinkühler; Philip Jones
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

5.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

6.  Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.

Authors:  Matthias Lauth; Asa Bergström; Takashi Shimokawa; Rune Toftgård
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

7.  GDC-0449-a potent inhibitor of the hedgehog pathway.

Authors:  Kirk D Robarge; Shirley A Brunton; Georgette M Castanedo; Yong Cui; Michael S Dina; Richard Goldsmith; Stephen E Gould; Oivin Guichert; Janet L Gunzner; Jason Halladay; Wei Jia; Cyrus Khojasteh; Michael F T Koehler; Karen Kotkow; Hank La; Rebecca L Lalonde; Kevin Lau; Leslie Lee; Derek Marshall; James C Marsters; Lesley J Murray; Changgeng Qian; Lee L Rubin; Laurent Salphati; Mark S Stanley; John H A Stibbard; Daniel P Sutherlin; Savita Ubhayaker; Shumei Wang; Susan Wong; Minli Xie
Journal:  Bioorg Med Chem Lett       Date:  2009-08-15       Impact factor: 2.823

8.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

Review 9.  Targeting of Smoothened for therapeutic gain.

Authors:  Martial Ruat; Lucile Hoch; Hélène Faure; Didier Rognan
Journal:  Trends Pharmacol Sci       Date:  2014-04-01       Impact factor: 14.819

10.  Structure and function of the Smoothened extracellular domain in vertebrate Hedgehog signaling.

Authors:  Sigrid Nachtergaele; Daniel M Whalen; Laurel K Mydock; Zhonghua Zhao; Tomas Malinauskas; Kathiresan Krishnan; Philip W Ingham; Douglas F Covey; Christian Siebold; Rajat Rohatgi
Journal:  Elife       Date:  2013-10-29       Impact factor: 8.140

View more
  4 in total

1.  Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.

Authors:  Jennifer R Pace; Albert M DeBerardinis; Vibhavari Sail; Silvia K Tacheva-Grigorova; Kelly A Chan; Raymond Tran; Daniel S Raccuia; Robert J Wechsler-Reya; M Kyle Hadden
Journal:  J Med Chem       Date:  2016-04-06       Impact factor: 7.446

2.  Formulation and evaluation of itraconazole liposomes for Hedgehog pathway inhibition.

Authors:  Jennifer R Pace; Rajan Jog; Diane J Burgess; M Kyle Hadden
Journal:  J Liposome Res       Date:  2019-10-02       Impact factor: 3.648

3.  Structure-Activity Relationship Studies of Hydantoin-Cored Ligands for Smoothened Receptor.

Authors:  Yang Liu; Fang Zhou; Kang Ding; Dongxiang Xue; Zhihao Zhu; Cuixia Li; Fei Li; Yueming Xu; Fei Xu; Zhiping Le; Suwen Zhao; Houchao Tao
Journal:  ChemistryOpen       Date:  2021-10       Impact factor: 2.630

4.  A structurally guided dissection-then-evolution strategy for ligand optimization of smoothened receptor.

Authors:  Lintao Ye; Kang Ding; Fei Zhao; Xiaoyan Liu; Yiran Wu; Yang Liu; Dongxiang Xue; Fang Zhou; Xianjun Zhang; Raymond C Stevens; Fei Xu; Suwen Zhao; Houchao Tao
Journal:  Medchemcomm       Date:  2017-04-28       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.